The aim of the suggested study is to assess the added value of 68Ga-FAPI-04 PET/CT over 18F-FDG PET/CT in evaluating the extent of disease in patients with various malignancies, in whom a diagnostic challenge is met, such as inconclusive findings on 18F-FDG PET/CT or other imaging studies, better delineation of tumor extent prior to therapy, and with emphasis on malignancies known to show variable avidity to FDG and at times, no uptake at all. Also patients unable to optimally comply with the required preparation for FDG imaging, such as diabetic patients who struggle in achieving glycemic control.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
50
* Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days. * Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists. * Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression.
Tel Aviv Sourasky medial center
Tel Aviv, Israel
RECRUITINGPatients who preformed 68Ga-FAPI-04 PSMA.
To evaluate the avidity of various cancers to 68Ga-FAPI-04.
Time frame: 1 year
Patients who preformed 68Ga-FAPI-04 PSMA and PET/CT FDG.
To compare the detectability of FAPI-04 and FDG for malignant lesions.
Time frame: 1 year
Patients who preformed 68Ga-FAPI-04 PSMA and PET/MRI.
To evaluate the potential impact of 68Ga-FAPI-04 PET/CT and/or PET/MRI on patient management.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.